|
1.4 BIOLOGIE - TECHNOS
|
|
|
|
2.11 ETIOLOGIE - ALIMENTATION
|
|
|
Artificial Sweeteners, Not Good, Not Bad [NY Times]
|
|
|
|
|
|
Researchers looked at 35 observational studies and 21 controlled trials of nonsugar sweeteners in children and adults. Some compared intake of sweeteners with no intake; others compared lower with higher intakes. They found no convincing evidence that nonsugar sweeteners had any effect in adults on eating behavior, cancer, cardiovascular disease, kidney disease, mood, behavior or cognition.
|
|
|
|
|
|
|
2.5 ETIOLOGIE - GÈNES
|
|
|
|
5. TRAITEMENTS
|
|
|
|
Sponge offers hope of 'less toxic' chemotherapy [BBC News]
|
|
|
|
|
|
Scientists believe they may have found a way to make cancer chemotherapy treatment less toxic to the body. They have begun testing a tiny sponge that sits inside a vein and removes excess chemo drugs from the blood once they have attacked the target tumour.
|
|
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
Designer protein delivers signal of choice [Nature]
|
|
|
|
|
|
A computational strategy has delivered a redesigned, more stable version of a cytokine protein that mimics the natural protein’s interactions with receptors, opening the way for designer cytokine-based therapeutics.
|
|
|
|
|
|
|
|
Researchers redesign a cancer-busting protein—without the side effects [Science]
|
|
|
|
|
|
For patients with aggressive kidney and skin cancers, an immune-boosting protein called interleukin-2 (IL-2) can be a lifesaver. But the dose at which it fights cancer can also produce life-threatening side effects. Now, scientists have used computer modeling to design a new protein from scratch that mimics IL-2’s immune-enhancing abilities, while avoiding its dangerous side effects. The protein has so far been tested only in animals, but it may soon enter human trials.
|
|
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
5.12.7 IMMUNOTHÉRAPIES - VACCINS
|
|
|
Progress in the fight against brain cancer [Nature]
|
|
|
|
|
|
The new vaccine studies show that supporting treatments such as the steroid dexamethasone can hamper the potency of immune responses. They also suggest that responses can be raised against both mutated and non-mutated tumour-related proteins, and show how these responses can be limited by immune-cell exhaustion.
|
|
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer [NICE]
|
|
|
|
|
|
Pembrolizumab, with pemetrexed and platinum chemotherapy is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. It is only recommended if: pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses and the company provides pembrolizumab according to the managed access agreement.
|
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
Rewiring R&D: The FierceBiotech JPM 2019 breakfast debate [Fierce Biotech]
|
|
|
|
|
|
For years, there’s been a lot of talk about artificial intelligence (AI), machine learning (ML) and digital in general around biopharma R&D, but often it can get trapped in a loop of hyperbole and big promises. We wanted to cut through some of the ambiguity around just what it means, how it can help drug development and ultimately, patients.
|
|
|
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
Regorafenib for previously treated advanced hepatocellular carcinoma [NICE]
|
|
|
|
|
|
Regorafenib is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had sorafenib, only if: they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and the company provides it according to the commercial arrangement.
|
|
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
Gauging Progress Against Cervical Cancer [Cancer Research Catalyst]
|
|
|
|
|
|
Given that January was named after the Roman god Janus, whose two faces allowed him to look both backward into the old year and forward into the new one, it seemed a good time to look back at the progress we made against cervical cancer in 2018 and to look for ways to build on the progress and further reduce the incidence and mortality of the disease in the future.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
Cancer Death Rate Continues to Decline [Science-Based Medicine]
|
|
|
|
|
|
The title of this post is similar to my post from one year ago – because the death rate from cancer is, in fact, continuing to decline, as it was a year ago. This is good news, reflecting several trends. It also is in direct contradiction to the typical alternative medicine, pseudoscience, everything-is-killing-you narrative spread by promoters of dubious treatments.
|
|
|
|
|
|
|
6.10 POLITIQUES
|
|
|
EU survey 2018 [BMA]
|
|
|
|
|
|
A BMA survey of over 1,500 EU doctors working in the UK has found that less than a quarter have faith in the Prime Minister's commitment to protect their rights in the event of a no-deal Brexit, with over a third making plans to move abroad following Brexit.
|
|
|
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|